Protected: Generis Celebrates New Milestone: Egyptian Drug Authority Chooses EXTEDOpulse Powered by CARA
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.

Immunic Therapeutics Selects CARA Life Sciences Platform to Streamline Regulatory Operations and Accelerate Submissions CARA Life Sciences Platform Adoption Continues to Grow with Biotech Organisation

Loba biotech GmbH, a wholly owned GMP manufacturing subsidiary of pharmaand GmbH (pharma&), has chosen Generis’ CARA Life Sciences Platform to launch its digital Quality

AI-powered CARA Platform and new Starter Pack Model fuel rapid expansion across regulated sectors LONDON, UK – Generis, creator of the CARA Platform and CARA

Cytonics, a biotechnology research and development company specializing in diagnostics and therapeutics for osteoarthritis, has selected Generis, the provider of the AI-enabled CARA Life Sciences

Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis,
© Copyright 2002-2026, Generis Enterprise Technology Limited, all rights reserved